ASCO data for Blueprint's BLU-667 competitive with Lilly's LOXO-292 in RET-altered cancers

Updated data for Blueprint's BLU-667 in RET-altered cancers presented Monday at the American Society of Clinical Oncology meeting in Chicago show that the compound could be competitive with fellow RET inhibitor LOXO-292 from Eli Lilly in RET-mutated NSCLC and thyroid cancers.

BLU-667 also showed impressive responses in a subpopulation of treatment-naïve Ret proto-oncogene (RET) fusion-positive non-small cell lung cancer (NSCLC) patients, and Blueprint Medicines Corp. (NASDAQ:BPMC) said it is working to expand enrollment in the first-line cohort to support seeking accelerated approval in the population. The company disclosed for the first time plans to submit an NDA to FDA in 1H20 for BLU-667 to treat RET-mutant medullary thyroid cancer (MTC) in patients previously treated with an approved multikinase inhibitor...